Johnson & Johnson stock: Erste Group downgrades rating from Buy to Hold

Published on 10/21/2026 at 16:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Johnson & Johnson stock stands at USD 616.4 billion. It costs EUR 227.35 on October 21, 2026, down 1.69 percent versus the Xetra close.

Rating and valuation

Erste Group downgraded Johnson & Johnson from Buy to Hold on October 21, 2026.
The consensus target was USD 279.41 from 22 analysts on October 20, 2026.
Johnson & Johnson stock costs EUR 227.35 at Lang & Schwarz on October 21, 2026 at 4:10 p.m. CEST, 1.69 percent below the Xetra close of October 20, 2026, and 19.12 percent below the 52-week high.
A USD 1.34 dividend per share is payable on December 8, 2026.

Architectural interior of a modern pharmaceutical research campus with a soaring glass-walled atrium, a long rectangular reflecting pool through its center, white-coated researchers walking past lush indoor plants, clean white concrete columns bathed in d — Johnson investiert in Pharma Forschung, US4781601046 Atrium mit Wasserbecken und hellem Tageslicht, Illustration mit AI erstellt.

Erste Group downgraded Johnson & Johnson from Buy to Hold in a research report issued on October 21, 2026, according to MarketBeat. Johnson & Johnson stock was trading at EUR 227.35 at Lang & Schwarz on October 21, 2026 at 4:10 p.m. CEST, down 1.69 percent versus the Xetra close of October 20, 2026.

Consensus target stays above price

The broader analyst picture remains higher than the latest US quotation. Investing.com listed an average 12-month target of USD 279.41 from 22 analysts on October 20, 2026. Against the NYSE quotation of USD 255.78 on October 21, 2026 at 10:21 a.m. ET, that target stood 9.24 percent higher.

Stock sits below its yearly high

The NYSE quotation was down 1.38 percent at USD 255.78 on October 21, 2026 at 10:21 a.m. ET, while the 52-week range was USD 184.66 to USD 281.07. The latest quotation was 9.88 percent above the yearly low and 8.99 percent below the yearly high. Johnson & Johnson had a market capitalization of USD 616.4 billion and a price-to-earnings ratio of 38.77 on the same date.

Dividend date adds an income marker

MarketBeat reported on October 15, 2026 that Johnson & Johnson maintained a fourth-quarter cash dividend of USD 1.34 per share, payable on December 8, 2026. The payment date gives the valuation discussion a concrete calendar point, while the rating change adds a more cautious counterweight to the consensus target.

Comparison with peers

Johnson & Johnson: down 1.69 percent versus the Xetra close, price-to-earnings ratio 38.77, market capitalization USD 616.4 billion.
Pfizer: down 0.85 percent on the NYSE, price-to-earnings ratio 39.46, market capitalization USD 170.2 billion.
Abbott Laboratories: down 2.53 percent on the NYSE, price-to-earnings ratio 32.20, market capitalization USD 172.8 billion.

Price and investor perspective

The German quotation was below its October 20 Xetra close as the US listing also traded lower. The combination of a USD 279.41 consensus target, a USD 1.34 dividend and the new Hold rating leaves valuation and execution as the key reference points for the stock.

The further course of trading is shown by the continuously updated real-time quote of Johnson & Johnson stock.